Pulse Biosciences, Inc. has announced that late-breaking data from its nPulse Cardiac Catheter Ablation System first-in-human feasibility study in Europe has been accepted for presentation at the 31st Annual AF Symposium, scheduled for February 2026. The presentation, to be delivered by Dr. Vivek Reddy of the Mount Sinai Fuster Heart Hospital, will include 6-month and 12-month follow-up data from the study. The company intends to provide specific presentation times in late January. The results have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulse Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260106087962) on January 06, 2026, and is solely responsible for the information contained therein.